Technology evaluation: ALVAC-CEA/B7.1, Aventis Pasteur/Therion.
Therion Biologics, in collaboration with Aventis Pasteur, is developing ALVAC-CEA/B7.1, a recombinant, pox virus-based vaccine that targets carcinoembryonic antigen (CEA) found on the surface of lung and colorectal tumor cells, for the potential treatment of lung and colorectal cancer. The vaccine is in phase II clinical trials for these indications.